Verve Therapeutics, Inc. Common Stock
VERV Real Time Price USDRecent trades of VERV by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by VERV's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Base editing of angptl3 and methods of using same for treatment of disease Oct. 15, 2024
-
Patent Title: Base editing of pcsk9 and methods of using same for treatment of disease Jul. 09, 2024
-
Patent Title: Lipid formulations for gene editing Jul. 02, 2024
-
Patent Title: Compositions and methods for targeted rna delivery Oct. 31, 2023
-
Patent Title: Compositions and methods for targeted rna delivery Dec. 28, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of VERV in WallStreetBets Daily Discussion
Recent insights relating to VERV
Recent picks made for VERV stock on CNBC
ETFs with the largest estimated holdings in VERV
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view VERV Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.